SINT SINTX TECHNOLOGIES INC.

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

Seasoned Healthcare Executive to Lead Strategic Growth Initiatives

Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX’s growth initiatives and enhancing investor relations.

Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare sector. His career began on Wall Street as a stockbroker, transitioning into investment banking roles at various firms in New York City. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms with offices in New York and Austin, Texas, focusing on founding and funding breakthrough healthcare technologies.

Throughout his career, Mr. Honigblum has raised over half a billion dollars for various ventures. Notably, Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for $620 million.

“Gregg’s appointment as Chief Strategy Officer reflects our confidence in his ability to elevate SINTX’s financial and strategic position,” said Eric K. Olson, CEO of SINTX Technologies. “His successful career in emerging technologies and deep investment banking knowledge will be invaluable as we pursue new development opportunities, strengthen investor relationships, and drive our corporate strategy and revenue forward.”

Mr. Honigblum’s deep understanding of the Company’s mission and strategic goals, coupled with his experience as a former member of the board of Amedica, the predecessor of SINTX, positions him to drive the Company’s corporate strategy effectively.

“I am honored to join SINTX at this pivotal juncture,” said Gregg R. Honigblum, Chief Strategy Officer. “The Company’s ongoing development of pioneering technologies in the medical device sector positions it at the forefront of commercialization. I look forward to contributing to the team’s efforts in enhancing shareholder value and drive the Company’s vision forward.”

For more information, please visit

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.

Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
19/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expa...

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX T...

 PRESS RELEASE

SINTX Technologies to Participate in Noble Capital Markets’ Emerging G...

SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company’s participation comes at an important stage in its evolution, following a period o...

 PRESS RELEASE

SINTX Technologies to Participate in Sidoti & Company Investor Confere...

SINTX Technologies to Participate in Sidoti & Company Investor Conference SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: To schedule a one-on-one meeting with SINTX Technologies’ management team, please email KCSA Strategic ...

 PRESS RELEASE

SINTX Technologies, AI 적용한 3D 프린팅 환자 맞춤형 임플란트 위한 실리콘 나이트라이드–PEEK 복합소재 ...

SINTX Technologies, AI 적용한 3D 프린팅 환자 맞춤형 임플란트 위한 실리콘 나이트라이드–PEEK 복합소재 제조 위해 EVONIK과 계약 체결 SiN/PEEK 맞춤 장비 생산에 즉시 착수할 수 있게 돼 미국 유타주 솔트레이크시티, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 첨단 세라믹과 생체소재 회사인 SINTX Technologies, Inc.(나스닥명: SINT) (이하 “SINTX” 또는 “회사”)가 특허를 획득한 실리콘 나이트라이드-PEEK 복합소재(SiN/PEEK) (미국 특허 제10,806,831호)를 제조하기 위해 고성능 폴리머 분야의 글로벌 선도 기업 Evonik Corporation(“EVONIK”)과 공급 계약을 체결했다. 이 소재는 SINTX의 미국 생산 설비에 이미 설치된 장비를 활용하고 AI를 적용해 생산될 예정인 환자 맞춤형 임플란트의 적층 제조를 위해 설계되었다. 이 계약에 따라 EVONIK은 상업 규모의 생산 역량을 활용해 Sin/PEEK 복합소재를 생산하게 되며, 이에 따라 회사는 AI 설계를 바탕으로 3D 프린팅한 환자 맞춤형 임플란트 제조를 즉시 시작할 수 있게 되었다. SIN...

 PRESS RELEASE

SINTX Technologies Menandatangani Perjanjian Bekalan dengan EVONIK unt...

SINTX Technologies Menandatangani Perjanjian Bekalan dengan EVONIK untuk Menghasilkan Sebatian Silikon Nitrida–PEEK untuk Implan Khusus Pesakit Berbantukan AI, Cetakan 3D Pencapaian ini membolehkan pengeluaran segera peranti tersuai SiN/PEEK SALT LAKE CITY, Utah, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” atau “Syarikat”), sebuah syarikat seramik dan biobahan termaju, hari ini mengumumkan bahawa ia telah menandatangani perjanjian bekalan dengan Evonik Corporation (“EVONIK”), peneraju global dalam polimer berprestasi tinggi, untuk mengeluarkan seba...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch